Abstract Multiple sclerosis is a neurologic disease caused by immune cell infiltration into the central nervous system, resulting in gray and white matter inflammation, progressive demyelination, and neuronal loss. Astrocytes, the most abundant cell population in the central nervous system (CNS), have been considered inert scaffold or housekeeping cells for many years. However, recently, it has become clear that this cell population actively modulates the immune response in the CNS at multiple levels. While being exposed to a plethora of cytokines during ongoing autoimmune inflammation, astrocytes modulate local CNS inflammation by secreting cytokines and chemokines, among other factors. This review article gives an overview of the most recent understanding about cytokine networks operational in astrocytes during autoimmune neuroinflammation and highlights potential targets for immunomodulatory therapies for multiple sclerosis.
Introduction
Astrocytes are the most abundant cell population in the human central nervous system (CNS) and account for one third of the cells in the murine CNS. Yet, defining their particular function has been a difficult undertaking. So far, morphologic criteria (star-shaped, protoplasmic vs fibroblastic), the expression of glial fibrillary acidic protein (GFAP), and other markers like Aldh1l1 are used to define this population, yet are neither innor exclusive. Astrocytes are a heterogenous population not only with respect to their morphological characteristics. It has recently become clear that the morphological variety of astrocytes is reflected by distinct functions. Depending on their location in the CNS (e.g., spinal cord vs frontal white matter vs cortical gray matter) and their association to adjacent brain structures, astrocyte's activities span from providing structural support, forming extracellular matrix, maintaining stable extracellular ion and neurotransmitter conditions, and forming and regulating the blood-brain barrier to modulating synaptic function in Btripartite synapses^between neurons and astrocytes. Thus, addressing astrocytes as one unique population may not reflect their multifaceted role in the healthy CNS.
Another degree of complexity is added when analyzing the function of astrocytes during multiple sclerosis and its murine model experimental autoimmune encephalomyelitis (EAE). It has become clear that all of the functions outlined above are modulated during ongoing inflammation by interactions between astrocytes and infiltrating immune cells. However, even before the breakdown of the blood-brain barrier, cytokines produced in the peripheral immune compartment get access to the CNS. Astrocytes, being part of the blood-brain barrier, are among the first to encounter these cytokines and react by producing inflammatory mediators such as chemokines and cytokines of their own without the need of direct cellular contact.
Based on these observations, this review will focus on the regulation of astrocyte activity during multiple sclerosis and its animal model-experimental autoimmune encephalomyelitis, EAE. We will also highlight potential links to novel therapeutic strategies derived from these observations and conclude with open questions worthy of further study.
Role of selected pro-and anti-inflammatory cytokines
In this first section, we will review the most recent advancements and experimental work of select pro-and antiinflammatory cytokines on astrocyte biology during inflammatory diseases of the CNS. Figure 1 summarizes the cellular sources of the mentioned cytokines.
Interferon-γ
Interferon-γ is produced by members of both the adaptive and innate immune system and is the signature cytokine of pathogenic Th1 cells. Its role during autoimmune inflammation is context specific and depends on multiple factors such as disease stage, cytokine environment and availability as well as activation status of antigen-presenting cells. One of the strongest cellular effects of interferon-γ is the upregulation of MHC-II on antigen-presenting cells to induce their ability to present antigen and prime CD4 T cells [1] . Astrocytes, as opposed to microglia and oligodendrocytes, express high levels of IFNGR1 [2] in vivo and upregulate MHC-II expression upon stimulation with interferon-γ in vitro [3] , emphasizing their potential function as local antigen-presenting cells in the CNS. In this context, early in vitro investigations demonstrated that expression of low levels of MHC-II on nonactivated astrocytes results in a decrease of T cell proliferation [4] and induces hyporesponsiveness of T and B cells [5] , potentially via secretion of the downmodulatory cytokine IL-27 [6, 7] . In contrast, when activated with interferon-γ, the ability of astrocytes to produce IL-27 is impaired resulting in increased proliferation and pathogenic potential of MOGspecific T cells ex vivo [6] . The ability of astrocytes to prime naive CD4 T cells, however, is still controversial and might also be dependent on the expression of costimulatory molecules, which are only in part expressed on astrocytes [8, 9] . Taken together, these observations, which were mainly obtained in vitro, point toward a proinflammatory net effect of interferon-γ on astrocytes.
In vivo studies using mice with astrocyte-specific dominant negative interferon-γ receptor expression (H-2 b GFAP/IFN-γR1ΔIC) exhibit more severe EAE and especially fail to recover during later stages of the disease. Mechanistically, an increase in demyelination and axonal loss in KO mice, mediated by enhanced production of proinflammatory mediators (CCL2, CCL5, CXCL10, IL-6, iNos, IL-1, TNF) in combination with elevated expression of MHC-II on microglia, were considered responsible for the failure of recovery in these KO mice. In contrast to these observations in vitro, IL-27 was induced by interferon-γ in vivo mediating increased availability of inflammation-resolving IL-10 [10] .
The above cited study suggested a role for interferon-γ-mediated signaling on astrocytes specifically during late stages of the disease, when downmodulatory and reparative mechanisms are mostly dependent on astrocytes driving remodeling of the injured tissue and depend on the availability of astrocytic interferon-γ signaling. However, potential sequestration in overall bioavailable interferon-γ due to binding to the dominant negative receptor may have influenced the results of this study. Further investigation using inducible KO models during different stages of the disease is thus needed to validate these findings and further investigate the role of interferon-γ on astrocytes. To date, interferon-γ signaling in astrocytes seems to have distinct functions depending on induction, peak, or recovery phase of CNS inflammation. This is exemplified by the dichotomy of the presumably proinflammatory effects of MHC-II upregulation on astrocytes during early disease stages as opposed to its effect in late-disease stages, where it initiates and perpetuates reparative mechanisms.
IL-17A
The founding family member of the IL-17 family of cytokines IL-17A has profound effects on different resident cell types in the CNS during inflammatory, ischemic, and degenerative diseases (reviewed in [11] ), and its impact on astrocytes has been under investigation ever since the discovery of IL-17A in 1993 [12] . Both murine [13] and human [14] astrocytes express IL-17RA, and its activation upon binding of IL-17A is translated into recruitment of Act1 and ultimately activation of NF-κB [11] . In vitro, stimulation of murine and human astrocytes with IL-17A leads to the induction of a proinflammatory state characterized by the production of various cytokines and chemokines (IL-6, TNF-α, CCL2, CCL3, CCL20, CXCL1, CXCL2, CXCL9, CXCL10, CXCL11), and these transcripts were also detected in astrocytes during EAE [11, [14] [15] [16] [17] [18] . In addition, blockade of IL-17A by the monoclonal antibody secukinumab reduces human astrocyte activation as indicated by IL-6 production [14] . Deficiency of IL-17RA in astrocytes has been experimentally mimicked by strategies targeting Act1 directly downstream of IL-17RA both by permanent astrocyte-conditional knockout as well as lentiviral knockdown at different stages of EAE with comparable results. In mice lacking Act1 in neuroectoderm-derived cells (Nestin Cre Act1 fl/fl , affecting neurons, astrocytes, and oligodendrocytes), EAE severity was markedly reduced with astrocytes being the main IL-17-responsive and disease-mediating population [19] . In line with these findings, targeting Act1 in astrocytes by lentiviral knockdown (shAct1) during induction, onset, and peak of EAE ameliorated the disease while reducing infiltrating inflammatory cells and percentage of Th17 cells in the CNS. This effect was attributed to a reduction in Th17-related mediators in total spinal cord RNA preparations (IL-17A/F, IL-23, IGF1, fibroblast growth factor-2 (FGF-2), MMP3, CXCL1, CXCL2, CXCL20) [20] . This finding could be reproduced to some extent using an astrocyte-conditional knockout strategy (GFAP Cre Act1 Molecules further downstream in IL-17RA signaling, such as NF-κB and its negative regulator ubiquitin-modifying enzyme A20, have also shown astrocyte-intrinsic effects on CNS inflammation [11, 24] . Taken together, astrocyte-intrinsic IL-17A-mediated signaling seems to promote CNS inflammation. However, recent conflicting data concerning the effects of IL-17A on neuronal stem cells and oligodendrocyte precursor cells [25] highlight the need for further investigations before targeting this immune axis in cell-type-specific therapies for multiple sclerosis.
IL-1β
IL-1β, a proinflammatory member of the IL-1 family of cytokines released not only by macrophages, monocytes, microglia, and brain endothelial cells [26] , has been shown to affect astrocytes during inflammatory CNS diseases. In in vitro studies, IL-1β was demonstrated to increase bloodbrain barrier (BBB) permeability in an astrocyte-intrinsic sonic-hedgehog protein-dependent manner to induce chemotactic CCL2, CCL20, and CXCL2 in astrocytes exacerbating BBB disruption and ultimately promoting influx of inflammatory cells [27, 28] . IL-1β has also been shown to activate Hif-1α, resulting in angioneogenesis and increased BBB permeability [29] .
Astrocytic metabolism has also been demonstrated to be influenced by IL-1β: IL-1β upregulates purinergic receptor P2X7 in human astrocytes in vitro to react to changing concentrations of extracellular ADP and ATP [30] . Moreover, both in vitro and in vivo IL-1β have been demonstrated to promote expression of astrocytic heme oxygenase-1 expression and the deposition of mitochondrial iron [31] . These signals have been demonstrated to induce a reactive astrocyte state that favors astrogliosis and chronic inflammation [32] . On the subcellular level, IL-1β results in the NF-κB-dependent production of proinflammatory cytokines such as CCL2, CCL20, and CXCL2, among others [33] .
Astrocytes also participate in the production of IL-1β in response to proinflammatory stimuli and thus form part of a positive feed-forward loop that maintains ongoing inflammation and tissue destruction. In these lines, therapeutic concepts such as the blockade of S1P receptors by FTY720 [34] , inhibition of COX2 signaling by analogs of celecoxib [35] , increase of cytosolic cGMP by sildenafil [36] , as well as other immunomodulatory drugs like resveratrol [37] , mitoxantron [38] , and dimethylumarate [39] have been demonstrated to inhibit IL-1β production in astrocytes during EAE, the cuprizone-induced model of demyelination in vivo as well as lipopolysaccharide (LPS)-induced astrocyte activation in vitro.
Thus, the existing knowledge about the action of IL-1β on astrocytes supports the concept of an overall proinflammatory role by the induction of a chemoattractant gradient, disruption of the blood-brain barrier as well as the impairment of cellular metabolism and the induction of chronic gliosis. Further mechanistic studies using targeted deletion of IL-1R1 in astrocytes, given its importance not only in Th17 differentiation [40, 41] , or with the IL-1β-neutralizing antibody canakinumab [42] may provide a deeper understanding of the role of IL-1β signaling in astrocytes and might point to novel cell-type-specific strategies with a potential role in treating late-stage disease.
IL-6
While astrocytic production of IL-6 has been used as a surrogate parameter to identify a bona fide proinflammatory phenotype in a multitude of experimental studies [24, 43, 44] , surprisingly limited knowledge exists about the functional role of astrocyte-derived IL-6 during EAE and multiple sclerosis. While global IL-6-deficient mice are resistant to EAE most likely due to defects in the interplay between innate and adaptive immunity during the priming phase causing failure to raise pathogenic T cell responses [45] , recent studies made use of transgenic mice with GFAP-driven expression of IL-6 on a globally IL-6-deficient background (GFAP-IL-6-IL-6 KO mice). These mice showed restored susceptibility to EAE with an atypical, ataxic phenotype which was driven by inflammation, demyelination, and astrogliosis sparing the spinal cord while mostly targeting the cerebellum, thus recapitulating a phenotype previously seen in GFAP-IL-6 overexpressing mice on a IL-6-sufficient background [46, 47] . These observations have profound implications and raise questions as to the importance of IL-6 produced in the periphery as well as the existence of cytokine spill from the CNS across the (intact?) blood-brain barrier during the priming phase of immune cells in the peripheral immune compartment. However, it has to be mentioned that in the model system used in these experiments, IL-6 is overexpressed under the control of GFAP promoter Bunphysiologically^, and without the need for its induction by other inflammatory stimuli [48] . Moreover, GFAP expressing cells have also been described in other organs including the gut, kidney, testes, skin, pancreas, and liver, among others [49] , raising the possibility of IL-6 produced in the peripheral immune compartment confounding the described effects.
In contrast to these studies underlining the generally assumed proinflammatory role of astrocyte-derived IL-6, astrocyte-conditional gp130-deficient mice, which are unable to respond to the IL-6 family of cytokines (including IL-6, IL-11, IL-27, leukemia inhibitory factor (LIF), oncostatin M, ciliary neurotrophic factor (CNTF), B cell-stimulating factor 3 (BSF3), and cardiotrophin-1 (CT-1), exhibit more severe EAE caused by increases in numbers and activation status of proinflammatory T cells, elevated apoptosis of astrocytes, and increased demyelination [50] . In this setting, gp130 signaling on astrocytes seems to be overall beneficial. This would argue against a positive autocrine proinflammatory feed-forward loop of astrocyte-derived IL-6 on astrocytes themselves. However, mutual compensatory mechanisms may be operational in this broad signaling-deficient system, which thus allows only for the judgment of the net effect of this cytokine family, but not for definite statements as to the contribution of a single cytokine, e.g., IL-6. Collectively, however, these studies suggest a proinflammatory role of astrocyte-derived IL-6. However, further studies are needed to decipher the role of astrocyte-derived IL-6 during CNS autoimmune inflammation and possible autocrine effects of astrocyte-derived IL-6.
Role of astrocyte-derived nitric oxide
Nitric oxide (NO), a free radical promoting mainly deleterious effects on resident cells in the CNS, is detected in elevated levels in inflammatory lesions and blood, urine, and cerebrospinal fluid (CSF) of MS patients [51] . Its production during ongoing inflammation has been attributed to the expression of the inducible form of the nitric oxide synthase (iNOS) in macrophages, endo-and epithelial cells, neurons, microglia as well as astrocytes by inflammatory stimuli like IL-1β, IL-17, and TNF [52, 53] . NO ultimately promotes inflammation and impairs reparative mechanisms by oligodendrocytes and their precursors [54] . Mechanistically, NO has been shown to inhibit the production of the blood-brain barrier integrity promoting chemokine CXCL12 in astrocytes through suppression of p38 MAPK [55] . Therapeutically, it has been shown that IFN-β, one of the main therapeutics of MS in the peripheral immune compartment, decreases NO production by a human astrocytoma cell line in vitro upon stimulation with proinflammatory cytokines [56] . Also, both human and murine astrocytes express sphingosine 1 phosphate receptors (S1P) and the immunomodulatory drug fingolimod reduces NO levels both in vivo and in vitro [4] . However, fingolimod failed to modulate primary progressive MS in the INFORMS study (Novartis, Miller DH et al. AAN 2013; P07.116), suggesting that its effects on CNS-resident cells might be celltype and disease-stage specific [57, 58] .
Moreover, few mechanistic studies exist addressing the effect of NO on astrocytes themselves. As mentioned above, since iNOS is expressed in most of the resident and infiltrating cell types during EAE and MS, reducing oxidative stress in general as opposed to astrocyte-derived NO only might provide the more valuable and promising therapeutic strategy.
Effect of anti-inflammatory IL-10 on astrocytes
IL-10 is a well-studied anti-inflammatory cytokine. The most important cellular sources in MS and EAE for IL-10 constitute certain CD4+ T helper cell subsets, namely Forkhead box protein 3 (FoxP3) expressing natural Treg cells (Tregs) and IL-10 producing T regulatory type 1 (Tr1) cells [59] . IL-10 has been shown to exert a multitude of mostly downmodulatory functions upon binding to its receptor, resulting in the termination of ongoing immune responses [60, 61] . Most of these immune mechanisms have been examined in hematopoietic and antigen-presenting cells such as T, B, and dendritic cells [62] .
Only recently, the downmodulatory effects of IL-10 on astrocytes are starting to be appreciated. In vitro, rat astrocytes preactivated with IL-17 and IFN-γ show increased expression of the chemokine CXCL12, which regulates blood-brain barrier integrity in a downmodulatory fashion (see below), upon exposure to IL-10 [63] . Moreover, activation of the cellular stress response, as determined by upregulation of heat shock protein 60 (Hsp60), has been demonstrated in human astrocytes upon IL-10 encounter [44] . Further mechanistic studies carried out in the Theiler's virus demyelination model (TMEV) have demonstrated that TMEV-infected murine astrocytes respond to IL-10 treatment with upregulation of IκBα mRNA impairing NF-κB translocation to the nucleus. This, in turn, abrogates NF-κB-induced expression of proinflammatory iNOS as well as COX-2 [64, 65] . Taken together, these studies demonstrate that IL-10 induces anti-inflammatory programs in astrocytes that downmodulate ongoing inflammation. Therapeutic approaches have already been taken to exploit this observation: IL-10 expression was induced in astrocytes during EAE upon their interaction with glatiramer acetate-specific T cells [66] . Adult neuronal stem cells genetically modified by a lentiviral vector to secrete IL-10 mitigate inflammation after intraventricular or intravenous injection during EAE, promote remyelination and oligodendrocyte differentiation of neuronal stem cells, and ultimately reduce astrogliosis causing an improved outcome after an inflammatory attack [67] .
Astrocytes have also been shown to produce IL-10: Human astrocyte cell lines stimulated with IFN-γ1a or combinations of proinflammatory cytokines (LPS/IFN-γ) plus IFN-γ1a produce IL-10, consistent with an anti-inflammatory program as reflected by reduced levels of iNOS [68] . TLR3 stimulation induces anti-inflammatory cytokines including IL-10 in adult human astrocytes and reduces the production of astrogliosis in terms of Bdysfunctional scars^hindering neuronal regeneration [69] . This observation was recapitulated in treatment experiments applying LPS to neonatal rats, which decreased proinflammatory responses in EAE at later age, as measured by increased IL-10 in the spinal cord [70] . However, conflicting results for TLR4 stimulation have been recently published for the treatment of pregnant mice with LPS, which show declined IL-10 production from mixed glial cultures from newborn mice restimulated with LPS [43] .
In human MS tissue, IL-10 (but not IL-10R) expression has been demonstrated histologically in chronic active MS lesions and the hypercellular rim of chronic active MS lesions in astrocytes [71] [72] [73] , which has risen the question of whether this expression of IL-10 might contribute to the perseveration of chronic inflammation and the formation of chronic active MS lesions. However, given the previously cited in vitro experiments, IL-10 production in chronic active lesions might also reflect (futile) counter regulation in response to chronic inflammation in these areas.
Taken together, further studies should address open questions as to the effects of IL-10 during autoimmune inflammation in animal experiments in vivo, the effects of TLR stimulation on astrocytic IL-10 production during different stages of ontogenesis, and the net effect of astrocyte-derived IL-10 during different stages of multiple sclerosis. To date, no astrocyteconditional IL-10 or IL-10R knockouts have been generated to address these questions.
Chemokines secreted by astrocytes
Chemokines modulate ongoing immune responses by recruiting distinct sets of immune cells to the site of inflammation. In multiple sclerosis and its animal model EAE, various chemokines have been identified as major players in the control of the immune response. In particular, astrocytes are an important source of chemokines, an important factor considering their strategic position at the interface between brain parenchyma and blood vessels at the blood-brain barrier, where they form not only a selective barrier for the entry of immune cells into the CNS but are also capable of secreting chemoattractant mediators into the blood circulation [74] . However, the current knowledge about the role of distinct astrocytic chemokines is limited. We will focus on the most recent studies of astrocytic chemokines involved in MS and EAE. An overview of the mentioned chemokines as well as select cytokines is depicted in Fig. 2 .
CCL2
CCL2 was initially purified in 1989 from the supernatant of the human astroglioma cell line U-105 MG as monomeric polypeptide with a molecular weight of approximately 13 kDa. Its predominant biological activity was determined as the chemoattraction of monocytes but not neutrophils; hence, it was termed Bmonocyte chemoattractant protein-1( MCP-1) and thought to be related to neoplastic diseases [75, 76] . Since then, extensive research has been undertaken to determine the role of CCL2 and its receptor CCR2 in infectious, inflammatory, and neoplastic diseases [77] . Not only monocytes, but also macrophages, basophils, mast cells, T cells, and microglia express CCR2 and are guided by a CCL2 gradient into different immunological niches.
In the context of autoimmune CNS inflammation, CCL2 remains the best-studied chemokine in multiple sclerosis and its animal model to date. Its cellular sources in the CNS have been determined by time course studies during EAE in different rodent strains [78, 79] as well as elegant approaches such as laser capture microdissection from different cell types in the inflamed CNS: Microvasculature endothelial cells and, to an even higher extent, astrocytes have been determined as the main resident cell sources of CCL2 in the CNS during EAE [80] .
In vitro, combinations of proinflammatory stimuli such as LPS, IL-1β, and TNF-α, potentiated by IFN-γ, but also glycolipids [81] induce the expression of CCL2 in murine astrocytes and promote chemotaxis of microglial cells and macrophages [82] . However, in vivo IFN-γ signaling seems to be dispensable for the induction of CCL2, since IFNGR −/− mice do not show alterations in the expression levels of CCL2 in the CNS [83] . Mechanistically, astrocytic CCL2 expression is controlled by binding of NF-κB to the CCL2 promoter and enhancer [84] as well as activation of stat1 [24] . Both of these transcription factors are modulated at multiple levels to induce ccl2 transcription, as exemplified by the activation of stat1 and NF-κB by ubiquitin-modifying protein A20 in astrocytes causing increased chemokine production in vitro and more severe EAE in vivo [24] . So far, three experimental studies have addressed the role of CCL2 production in astrocytes during EAE making use of astrocyte-conditional CCL2 knockout mice (GFAP Cre CCL2 fl/ fl ). All of them showed decreased disease severity, most pronounced during late-disease stages. As expected, based on CCL2's mode of action as a chemoattractant, the numbers of infiltrating macrophages and T cells were found to be reduced. Moreover, the activation status of macrophages, microglia, and astrocytes was shifted toward anti-inflammatory phenotypes, which was paralleled by reduced activation of astrocytes and microglia [85] . While most of these studies did not detect a change in T cell phenotype [86] , CD4 lymphocytes seemed to be confined to CNS perivascular spaces with an impaired ability to migrate through the glia limitans [87] . Paul et al. compared astrocytic vs endothelial CCL2 deficiency and found that expression of CCL2 in astrocytes regulates overall blood-brain barrier integrity by destabilizing endothelial tight junctions and ultimately enables leukocyte penetration into the CNS. In contrast, endothelial CCL2 gives the stimulus for the exit of leukocytes out of the blood vessel [86] . This mechanistic view explains their observations, in which endothelial CCL2-deficient mice showed delayed disease onset with comparable severity, while astrocyteconditional CCL2 deficiency causes a similar onset but reduced disease severity. Finally, GFAP Cre CCL2 fl/fl exhibit reduced long-term axonal loss and demyelination [87] . Interestingly, this seems not only to be the result of a decrease and mitigation of the proinflammatory infiltrate following a chemotactic stimulus, but is also caused by CNS-intrinsic CCL2 actions. In the murine model of TNF-α-induced demyelination (TID) that recapitulates some aspects of demyelination in multiple sclerosis, CCL2 was upregulated in astrocytes. Moreover, astrocytes themselves expressed CCR2 both in vivo and in vitro, migrated toward a CCL2 chemotactic gradient underlining the functionality of their CCR2, and showed decreased apoptosis upon CCL2 stimulation via induction of NF-κB by the PI3-kinase and Akt pathways [88] . Of note, in experiments using CCR2-deficient astrocytes, those effects were not entirely abolished pointing toward the existence of an alternative receptor for CCL2 on astrocytes. Already in 2003, this alternative receptor for CCL2 and other chemokines, named orphan mouse chemokine receptor L-CCR, was shown to be expressed on infiltrating macrophages, but not T cells, during EAE; moreover, L-CCR was also demonstrated to be expressed on astrocytes and microglia [89] and to be induced by LPS signaling in vivo and in vitro [90, 91] . Taken together (see Fig. 3 ), astrocytes not only produce CCL2 upon proinflammatory stimuli to promote BBB disruption, guide inflammatory cells into the CNS, shape their proinflammatory attributes, and ultimately promote axonal loss and neurodegeneration, but they also respond to CCL2 themselves by two discrete receptors promoting their survival and chemotaxis. In this partly autocrine positive feed-forward loop, astrocytic CCL2 plays a detrimental role and is thus worthy being considered for therapeutic approaches. Bindarit, a small synthetic indazolic derivative that preferentially inhibits transcription of the monocyte chemoattractant subfamily of CC chemokines (CCL2, CCL7, CCL8), has high BBB permeability and was shown to block the synthesis of CCL2 in astrocytes, microglia, and endothelial cells in vitro. Bindarit decreased CNS availability of CCL2 and ameliorated EAE with decreased incidence, onset, and severity in a preventive regimen [92] . Similarly, treatment with Fasudil, a Rho-kinase inhibitor, improved EAE clinical course by reducing proinflammatory cytokine production from astrocytes, including CCL2 [93] . Last, activation of estrogen receptor α (ERα) by estrogen receptor modulators ameliorates EAE by decreasing astrocytic CCL2 and CCL7 [84, 94] .
However, some of these therapeutic approaches are confined by side effects of the drug or lack of proof of efficiency in the human system. All in all, more selective and fine-tuned approaches will be needed targeting CCL2 expression in distinct subsets of CNS-intrinsic cells, e.g., by specific antagonization or knockdown strategies, in order to dampen autoimmune responses in the CNS without compromising or jeopardizing local immune surveillance.
CCL20
CCL20, previously termed macrophage inflammatory protein-3α (MIP-3α), is a CC motif chemokine functioning as a chemoattractant for cells expressing its receptor CCR6 including certain fractions of Th17 cells and T cells. It was first described in 1998 in EAE in vivo as well as in ischemic and MS brain tissue and was shown to be induced in vitro by TNF-α in astrocytes, microglia, and macrophage cultures [95, 96] . Since then, astrocytes have been demonstrated to be the main source of CCL20 production in response to proinflammatory stimuli such as TNF-α, IL-6, IL-17 (mainly in combination with IL-6), IL-1β, IL-9 as well as TLR3 and four ligands poly(I:C) and LPS in the CNS [14, 17, 33, [97] [98] [99] . Interestingly, IL-1β and TNF-α seem to be the most potent These transcription factors bind to the CCL2 promoter and its enhancer (2) . Favored by their intimate location at the blood-brain barrier, astrocytes secrete CCL2 into the circulation (3) creating a chemotactic gradient for cells expressing CCR2 such as T cells, mast cells, monocytes, or macrophages (4), which are guided to the site of inflammation (5). Also, autocrine effects of CCL2 upon binding of its receptors CCR2 and L-CCR, both expressed on astrocytes, lead to astrocytic migration toward a CCL2 gradient as well as reduced apoptosis (6) inducers of CCL20, while IFN-γ has no effect on its expression [28] . Following astrocyte activation by these proinflammatory stimuli, the transcription of CCL20 is induced by phosphorylation of NF-κB and activation of stat3 [17] . This pathway can be modulated by estrogen receptor signaling, since the selective estrogen receptor modulator raloxifene decreases astrocytic CCL20 production in vitro and during EAE [33] , most likely by inhibiting NF-κB and stat3-mediated signaling. The net effect of CCL20 during EAE is the attraction of T and B cells as well as immature dendritic cells, creating a proinflammatory milieu characterized mostly by Th17 cytokines, which further promotes the attraction of immune cells in a positive feed-forward loop [100] . So far, no astrocytespecific genetic knockout study exists; however, modification of this signaling pathway, as demonstrated for estrogen receptor modulators, might provide a promising strategy worthy of further investigation in EAE and MS.
CXCL8 (IL-8)
CXCL8, also known as IL-8 or neutrophil chemotactic factor, is well characterized for its role in viral [101] and protozoic [102] infections to attract neutrophils and, to a lesser extent than CCL2, monocytes [103] ; extensive studies have focused on its effects during inflammatory diseases like psoriasis or pulmonary conditions like COPD as well as its role in cancer promotion, metastasis, and angiogenesis. In these conditions, its role as a chemotactic agent for neutrophils as well as its role in angiogenesis is well characterized.
In the context of CNS autoimmune inflammation, CXCL8 expression in endothelial cells was found to promote Th1 recruitment [104] . In addition, CXCL8 is a member of the inflammatory Bsecretome^of astrocytes induced by TNF-α, IL-1β, and IFN-γ in vitro [105-107, 103, 108] as well as TLR3 signaling [109] . These observations suggest a role for CXCL8 in attracting inflammatory cells of both the innate and adaptive immune system, which promote inflammation and ultimately detrimental effects.
Challenging this conclusion, however, the beneficial effects of CXCL8 on remyelination after an autoimmune inflammatory attack have been recently reported. A study by Mohan et al. [110] suggests that CXCL8 and LIF are involved in the protective effects of FGF1: in a comparative screening of remyelinated and unmyelinated chronic MS lesions, the authors identified FGF1 as an putative inductor of remyelination. This hypothesis was further tested in vitro, when exposure of myelinating and organotypic cerebellar cultures showed enhanced myelination upon exposure to FGF1. This effect was dependent on the presence of astrocytes. Finally, exposure of astrocyte cultures to FGF1 led to the induction of LIF and CXCL8, both of which were thus suggested to be involved in the recruitment and differentiation of oligodendrocyte precursor cells (OPCs) and oligodendrocytes to promote remyelination [111] . Taking these observations together, CXCL8 is induced in astrocytes by FGF1 and might induce chemotaxis of OPCs and thus indirectly promote remyelination. These observations make astrocytic CXCL8 an interesting candidate for the promotion of remyelination and recovery after an inflammatory event even in later stages of the disease. However, further experimental studies are needed to corroborate and functionally validate these findings.
CXCL10
CXCL10 belongs to the CXC family of cytokines with a molecular weight of around 8.7 kDa. It has been described as an Binflammatory^chemokine mediating proinflammatory immune cell tissue infiltration and is best studied in the context of chronic viral infections such as hepatitis C [112] . As documented in several cell types including keratinocytes, hepatocytes, pancreatic acinar cells, as well as kidney mesangial cells [113] , expression of CXCL10 in astrocytes and microglia during EAE depends on the availability of immune cell-derived interferon-γ. This has been demonstrated by its absence in Ifngr −/− and Ifng −/− mice [83, 114] and its inducibility by adenovirus-encoded interferon-γ (AdIFNg) [115] , underlining the convenience of its previous name interferon-γ inducible protein 10 (IP-10) [78, 116] . Moreover, other proinflammatory stimuli (IL-1β, TNF-α) [117] as well as TLR3/4 signaling in mouse astrocytes [118, 119] induce CXCL10 production by astrocytes. In MS and EAE, expression of CXCL10 has been demonstrated in astrocytes surrounding inflammatory lesions [120] , where it attracts CXCR3+ Th1 cells and antibody secreting B cells during acute inflammation [121] . A recent study using an astrocyte-conditional knockout of CXCL10 proved astrocytes to be the main producers of CXCL10 in the CNS and detected diminished disease severity with delayed onset, which was attributed to reduction in CD4 T cell accumulation in perivascular spaces of the spinal cord, a decrease in the ratio of Th1 to Th17 cells as well as reduced acute spinal cord demyelination. However, progressive spinal cord axonal loss at later stages was not affected in these mice, altogether pointing toward a proinflammatory role of astrocytic CXCL10 in acute inflammation with little effect on chronic inflammatory or reparative processes such as remyelination [122] . Of note, in EAE studies using globally deficient mice for either CXCL10 or its receptor CXCR3, which is expressed mostly on Th1 cells and shared with the chemokines CXCL9 and CXCL11, contradictory findings exist and favor the anti-inflammatory effects of CXCL10 in EAE due to compartmentalization effects between perivascular space and parenchyma [8, 9] . However, in these studies, specific conclusions as to the role of astrocytederived CXCL10 are hampered by the use of systems globally deficient for CXCL10 or its (shared) receptor.
In the cuprizone model of demyelination, astrocyteproduced CXCL10 guides the microglia to sites of inflammatory damage for the removal of myelin debris, enabling remyelination [123] . These findings have been recently challenged by new studies in which early microglia activation by CXCL10 (not CCL2 or CCL3) has detrimental effects on oligodendrocyte survival, remyelination, and axonal damage [124] . In line with these observations, in vitro studies using human OPCs showed impaired differentiation when cocultured with proinflammatory T cells or macrophages, in part by indirect mechanisms mediated by astrocytic CXCL10 [125] .
The differences observed in these studies may reflect the use of different experimental models, readouts, and time points. Given the high expression of the receptor for CXCL10, CXCR3, on T cells in the CSF of MS patients, its elevation in the CSF of patients with active MS [126] as well as evidence for a role of CXCL10 in the promotion of demyelination and axonal damage during later disease stages [127] , further experimentation combining different experimental approaches with astrocyte-intrinsic deficiency of CXCL10 will be needed to clarify the value of targeting CXCL10 in the treatment of acute and late stages of multiple sclerosis.
CXCL12
CXCL12, also termed stromal cell-derived factor 1, is known as a key inhibitor of leukocyte entry into the CNS [128] [129] [130] . While most of the studies available focus on the expression of CXCL12 in endothelial cells of the luminal part of the bloodbrain barrier, several studies suggest a protective role for CXCL12 in astrocytes as well. First, IL-10 [61] has been shown to stimulate the expression of CXCL12 in rat astrocytes [63] , and astrocytic expression of CXCL12 induced by IL-10 is potentiated by TNF-α [131] . Second, neurotoxic NO inhibits CXCL12 expression in vitro and iNOS expression negatively correlates with the level of CXCL12 transcripts in astrocytes. In vivo, suppression of NO production recovers CXCL12 expression in the CNS [55, 132] . Third, astrocyte derived CXCL12 redirects the polarization of Th1 cells into CD25-Foxp3-IL-10+ antigen-specific regulatory T cells restraining the autoimmune inflammatory process in an IL-10-dependent manner, suggesting a positive feed-forward loop involving IL-10 and CXCL12 [133] . Taken together, these studies point toward a protective role of CXCL12 generated from astrocytes by mechanisms involving shifts in T cell polarization, dampening of proinflammatory mediators, and inhibition of immune cell entry into the CNS.
Conversely, earlier studies demonstrated that astrocytes themselves respond to CXCL12 by the release of potentially neurotoxic glutamate [134] . Moreover, Calderon et al. [135] reported that CXCL12 is expressed to a low extent by a small number of astrocytes in normal brain tissue and shows its highest expression in astrocytes in active MS lesions, followed by decreased expression in chronic lesions particularly in hypertrophic astrocytes near the lesion edge. In this study, proinflammatory IL-1β and MBP induced CXCL12 expression in astrocytes by signaling pathways involving ERK and Pi3-K, based on which the authors concluded that CXCL12 in astrocytes may initiate or augment the inflammatory response during MS [135] . However, these observations might reflect the expression of CXCL12 as a downmodulatory mechanism triggered by inflammation. Additional experiments should be carried out to determine whether CXCL12 induction represents a suitable tool to downmodulate CNS inflammation. Taken together, experimental models are consistent in the idea that CCL2 is essential for the recruitment of inflammatory cells into the CNS, while CXCL10 and CXCL12 might have a more context-dependent function and can actually inhibit inflammatory infiltrates in the CNS.
Conclusion
Astrocyte-derived cytokines and chemokines play important roles in the recruitment of immune cells into the CNS, shape the quality of the ongoing inflammation, and are involved in late-stage disease mechanisms such as chronic demyelination, axonal loss as well as reparative functions. As outlined in this article, some of these mediators promise a therapeutic potential for the treatment of different stages of multiple sclerosis. Future pharmacologic studies need to address the accessibility of these mediators for blocking or activation strategies in order to shape the quantity and quality of the immune response. A deeper understanding of cytokines and chemokines active in multiple sclerosis might therefore pave the way to novel therapies targeting specific aspects of astrocyte biology for MS and other neurologic diseases. 
